# US 2019/0314299 A1 · Putrescine topical barrier formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314299 A1
- Document ID: US20190314299A1
- Status: Published application
- Kind: A1
- Application number: 16/349,030
- Filed: 2018-01-05
- Published: 2019-10-17
- Earliest claimed: 2017-01-06
- Assignees: Vivier Canada Inc.
- Applicants: Vivier Canada Inc.
- Inventors: GHISLAIN VIVIER
- Web page: https://patentgrep.com/patent/US20190314299A1

## CPC

- A61K 31/132: having two or more amino groups, e.g. spermidine, putrescine
- A61P 17/00: Drugs for dermatological disorders
- A61K 8/31: Hydrocarbons
- A61K 8/34: Alcohols
- A61K 8/345: {containing more than one hydroxy group}
- A61K 8/40: containing nitrogen (quinones containing nitrogen A61K8/355)
- A61K 8/41: Amines
- A61K 8/466: {containing sulfonic acid derivatives; Salts}
- A61K 8/553: {Phospholipids, e.g. lecithin}
- A61K 8/673: {Vitamin B group}
- A61K 8/676: {Ascorbic acid, i.e. vitamin C}
- A61K 8/922: {of vegetable origin}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention describes stable topical barrier compositions comprising primary polyamines and uses thereof for protecting the skin from external stressors, for improving skin's moisture and fort stimulating healing of the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation, for increasing skin's moisture and/or for reducing or preventing skin's signs of aging.

## Claims

### Claim 1

A topical water free barrier composition comprising: (i) a polyamine; (ii) a phospholipid to encapsulate the primary polyamine; (iii) petroleum jelly; and (iv) mineral oil.

### Claim 2 (depends on 1)

The barrier composition of claim 1, wherein the polyamine is a primary aliphatic lower-alkyl (C1-5) monoamine, preferably aminoacetonitrile; a primary aliphatic alkylamine, preferably spermine or spermidine; or a primary aliphatic lower-alkyl (C1-5) polyamine, preferably putrescine or dansylcadaverine.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The barrier composition of claim 1, wherein the polyamine is aminoacetonitrile; spermine or spermidine; or putrescine or dansylcadaverine, preferably putrescine.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 4)

The barrier composition of claim 4, wherein the putrescine is in a concentration of between about 0.1% w/w to about 1% w/w; about 0.4% w/w; or about 0.8% w/w.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The barrier composition of claim 1, wherein the petroleum jelly is in a concentration of between about 25% w/w and 65% w/w; or about 45% w/w.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The barrier composition of claim 1, wherein the mineral oil is in a concentration of between about 30% w/w and about 45% w/w; or of about 35% w/w.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The barrier composition of claim 1, wherein the phospholipid is a quaternary ammonium salt.

### Claim 16 (depends on 15)

The barrier composition of claim 15, wherein the quaternary ammonium salt is cocamidopropyl PG-dimonium chloride phosphate.

### Claim 17 (depends on 16)

The barrier composition of claim 16, wherein the cocamidopropyl PG-dimonium chloride phosphate is in a concentration of between about 3% w/w and about 6% w/w; or about 4% w/w.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The barrier composition of claim 1, further comprising paraffin; (ii) lanolin oil; (iii) a lipophilic Vitamin C derivative; (iv) one or more humectants; and/or (v) bisabolol.

### Claim 20 (depends on 19)

The barrier composition of claim 19, wherein the paraffin is in a concentration of between about 3% w/w and 15% w/w; or about 8.5% w/w.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 19)

The barrier composition of claim 19, wherein the lanolin oil is in a concentration of between about 3% w/w and 6% w/w; or about 5% w/w.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 19)

The composition of claim 19, wherein the lipophilic Vitamin C derivative is in a concentration of between about 0.1% w/w and 10% w/w.

### Claim 27 (depends on 19)

The composition of claim 19, wherein the lipophilic Vitamin C derivative comprises 3-O-Ethyl Ascorbic Acid (3-O-EAA).

### Claim 28 (depends on 27)

The composition of claim 27, wherein the 3-O-EAA is in a concentration of about 0.5% w/w.

### Claim 29

(canceled)

### Claim 30 (depends on 19)

The barrier composition of claim 19, wherein the one or more humectants is(are) in a concentration of between about 0.5% w/w and 3% w/w.

### Claim 31 (depends on 19)

The barrier composition of claim 19, wherein the one or more humectants comprise(s) glycerin, vitamin B5 or a combination thereof.

### Claim 32 (depends on 31)

The barrier composition of claim 31, wherein the one or more humectants comprise(s) about 1% w/w of the glycerin and about 1% w/w of the Vitamin B5.

### Claim 33

(canceled)

### Claim 34 (depends on 19)

The barrier composition of claim 19, wherein the bisabolol is in a concentration of between about 0.1% w/w and 1% w/w; or about 0.5% w/w.

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39 (depends on 1)

A method of using the barrier composition defined in claim 1, for (i) treating or preventing skin inflammation, skin's signs of aging and/or skin irritation; (ii) promoting wound healing; or (iii) preventing or reducing the formation of hypertrophic scar tissue.

### Claim 40

(canceled)

### Claim 41

(canceled)
